Medirom Healthcare Technologies Stock Performance
| MRM Stock | USD 0.92 0.01 1.08% |
The company secures a Beta (Market Risk) of 2.94, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medirom Healthcare will likely underperform. At this point, Medirom Healthcare has a negative expected return of -1.48%. Please make sure to verify Medirom Healthcare's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Medirom Healthcare performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medirom Healthcare Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Disposition of 2500 shares by Cohen Edward H of Medirom Healthcare at 11.18 subject to Rule 16b-3 | 11/05/2024 |
2 | SBC Medical Group HoldingsMEDIROM Healthcare Technologies | 11/08/2024 |
3 | M3 Group Joins MEDIROM Mother Labs Series A Financing Round at JPY9 Billion Pre-Money Valuation | 12/02/2024 |
4 | M3 Group Joins MEDIROM Mother Labs Series A Financing Round at JPY9 Billion as of December ... | 12/06/2024 |
5 | MEDIROM Healthcare Technologies Has ReceivedOrders for Over 25,000 MOTHER Bracelet Units | 12/09/2024 |
6 | MEDIROM Healthcare dips 8, prices 5M ADS offering | 12/10/2024 |
7 | Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs Series A Financing at a Pre-Money Valuation of JPY9 Billion | 12/11/2024 |
8 | Communiqu de presse relatif la mise en uvre du retrait obligatoire de MRM | 12/12/2024 |
9 | MEDIROM Healthcare Technologys Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round | 12/13/2024 |
10 | MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators | 12/23/2024 |
11 | MEDIROM Reports December 2024 KPIs, Shows Growth in Salon and Health Tech Sectors - TipRanks | 01/29/2025 |
| Begin Period Cash Flow | 605.5 M |
Medirom |
Medirom Healthcare Relative Risk vs. Return Landscape
If you would invest 287.00 in Medirom Healthcare Technologies on November 4, 2024 and sell it today you would lose (195.00) from holding Medirom Healthcare Technologies or give up 67.94% of portfolio value over 90 days. Medirom Healthcare Technologies is generating negative expected returns assuming volatility of 7.998% on return distribution over 90 days investment horizon. In other words, 71% of stocks are less volatile than Medirom, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Medirom Healthcare Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medirom Healthcare's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medirom Healthcare Technologies, and traders can use it to determine the average amount a Medirom Healthcare's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1851
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRM |
Estimated Market Risk
| 8.0 actual daily | 71 71% of assets are less volatile |
Expected Return
| -1.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medirom Healthcare is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medirom Healthcare by adding Medirom Healthcare to a well-diversified portfolio.
Medirom Healthcare Fundamentals Growth
Medirom Stock prices reflect investors' perceptions of the future prospects and financial health of Medirom Healthcare, and Medirom Healthcare fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medirom Stock performance.
| Return On Equity | 1.47 | ||||
| Return On Asset | -0.036 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 29.4 M | ||||
| Shares Outstanding | 7.9 M | ||||
| Price To Book | 13.24 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 6.83 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | 310.08 M | ||||
| Net Income | 115.05 M | ||||
| Cash And Equivalents | 354.95 M | ||||
| Cash Per Share | 72.70 X | ||||
| Total Debt | 3.65 B | ||||
| Current Ratio | 0.36 X | ||||
| Book Value Per Share | 43.19 X | ||||
| Cash Flow From Operations | (631.74 M) | ||||
| Earnings Per Share | (0.15) X | ||||
| Market Capitalization | 7.33 M | ||||
| Total Asset | 6.85 B | ||||
| Retained Earnings | 80.28 M | ||||
| Working Capital | (1.8 B) | ||||
About Medirom Healthcare Performance
By examining Medirom Healthcare's fundamental ratios, stakeholders can obtain critical insights into Medirom Healthcare's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medirom Healthcare is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 8.74 | 9.18 | |
| Return On Tangible Assets | 0.02 | 0.03 | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.49 | 0.52 |
Things to note about Medirom Healthcare performance evaluation
Checking the ongoing alerts about Medirom Healthcare for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medirom Healthcare help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medirom Healthcare generated a negative expected return over the last 90 days | |
| Medirom Healthcare has high historical volatility and very poor performance | |
| Medirom Healthcare has some characteristics of a very speculative penny stock | |
| Medirom Healthcare has high likelihood to experience some financial distress in the next 2 years | |
| Medirom Healthcare Technologies has 3.65 B in debt. Medirom Healthcare has a current ratio of 0.35, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Medirom to invest in growth at high rates of return. | |
| Medirom Healthcare Technologies has about 354.95 M in cash with (631.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 72.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 40.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: MEDIROM Reports December 2024 KPIs, Shows Growth in Salon and Health Tech Sectors - TipRanks |
- Analyzing Medirom Healthcare's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medirom Healthcare's stock is overvalued or undervalued compared to its peers.
- Examining Medirom Healthcare's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medirom Healthcare's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medirom Healthcare's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medirom Healthcare's stock. These opinions can provide insight into Medirom Healthcare's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.